In recent years, advances in clinical research have led to the approval of several treatments for stage IV prostate cancer (PCa): two next-generation androgen receptor (AR)-directed therapies (abiraterone acetate and enzalutamide), a chemotherapeutic agent (cabazitaxel) and a radiopharmaceutical agent (radium-223). This evidence concerns the gene AR and prostate cancer.